Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial

Saira Z SheikhMorton A ScheinbergJames Cheng-Chung WeiDana TegzovaWilliam StohlRicardo Acayaba de ToledoTamara MucenicMauricio R Abello BanfiKathleen Maksimowicz-McKinnonCarlos Abud-MendozaSandra NavarraMercedes GarciaIgnacio Garcia-De La TorreJosep Ordi RosRoger A LevyDamon L BassJorge Ross TerrésRaj PunwaneyJulia HarrisAlireza NamiAmy PierceKevin S ThorneloeBeulah JiDavid A Roth2026-01-302026-01-302021-0210.1016/S2665-9913(20)30355-6https://scholars.csmu.edu.tw/handle/123456789/4139[SDGs]SDG3Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trialjournal-article